{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID", "Hypericum perforatum", "SARS-CoV-2", "antivirals", "coronavirus", "hypericin", "medicinal plants", "plant extract", "pseudohypericin"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35631357", "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "25"}], "Language": ["eng"], "ELocationID": ["530", "10.3390/ph15050530"], "Journal": {"ISSN": "1424-8247", "JournalIssue": {"Volume": "15", "Issue": "5", "PubDate": {"Year": "2022", "Month": "Apr", "Day": "25"}}, "Title": "Pharmaceuticals (Basel, Switzerland)", "ISOAbbreviation": "Pharmaceuticals (Basel)"}, "ArticleTitle": "<i>Hypericum perforatum</i> and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.", "Abstract": {"AbstractText": ["For almost two years, the COVID-19 pandemic has constituted a major challenge to human health, particularly due to the lack of efficient antivirals to be used against the virus during routine treatment interventions. Multiple treatment options have been investigated for their potential inhibitory effect on SARS-CoV-2. Natural products, such as plant extracts, may be a promising option, as they have shown an antiviral activity against other viruses in the past. Here, a quantified extract of <i>Hypericum perforatum</i> was tested and found to possess a potent antiviral activity against SARS-CoV-2. The antiviral potency of the extract could be attributed to the naphtodianthrones hypericin and pseudohypericin, in contrast to other tested ingredients of the plant material, which did not show any antiviral activity. <i>Hypericum perforatum</i> and its main active ingredient hypericin were also effective against different SARS-CoV-2 variants (Alpha, Beta, Delta, and Omicron). Concerning its mechanism of action, evidence was obtained that <i>Hypericum perforatum</i> and hypericin may hold a direct virus-blocking effect against SARS-CoV-2 virus particles. Taken together, the presented data clearly emphasize the promising antiviral activity of <i>Hypericum perforatum</i> and its active ingredients against SARS-CoV-2 infections."]}, "AuthorList": [{"Identifier": ["0000-0002-3651-6039"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Virology Muenster, Center for Molecular Biology of Inflammation (ZMBE), University Hospital Muenster, 48149 Muenster, Germany."}, {"Identifier": [], "Affiliation": "Department of Virology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Sharkia, Egypt."}], "LastName": "Mohamed", "ForeName": "Fakry F", "Initials": "FF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Virology Muenster, Center for Molecular Biology of Inflammation (ZMBE), University Hospital Muenster, 48149 Muenster, Germany."}], "LastName": "Anhlan", "ForeName": "Darisuren", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Virology Muenster, Center for Molecular Biology of Inflammation (ZMBE), University Hospital Muenster, 48149 Muenster, Germany."}], "LastName": "Sch\u00f6fb\u00e4nker", "ForeName": "Michael", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Virology Muenster, Center for Molecular Biology of Inflammation (ZMBE), University Hospital Muenster, 48149 Muenster, Germany."}], "LastName": "Schreiber", "ForeName": "Andr\u00e9", "Initials": "A"}, {"Identifier": ["0000-0002-2745-5748"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmaceutical Biology and Phytochemistry, University of Muenster, 48149 Muenster, Germany."}], "LastName": "Classen", "ForeName": "Nica", "Initials": "N"}, {"Identifier": ["0000-0003-0886-8384"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmaceutical Biology and Phytochemistry, University of Muenster, 48149 Muenster, Germany."}], "LastName": "Hensel", "ForeName": "Andreas", "Initials": "A"}, {"Identifier": ["0000-0002-5790-6423"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Clinical Pharmacy, Institute of Pharmaceutical and Medical Chemistry, University of Muenster, 48149 Muenster, Germany."}], "LastName": "Hempel", "ForeName": "Georg", "Initials": "G"}, {"Identifier": ["0000-0003-0269-685X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hirsch Apotheke, 58507 Luedenscheid, Germany."}], "LastName": "Scholz", "ForeName": "Wolfgang", "Initials": "W"}, {"Identifier": ["0000-0003-2992-1471"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Clinical Virology, Institute of Virology, University Hospital Muenster, 48151 Muenster, Germany."}], "LastName": "K\u00fchn", "ForeName": "Joachim", "Initials": "J"}, {"Identifier": ["0000-0003-3145-5887"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Virology Muenster, Center for Molecular Biology of Inflammation (ZMBE), University Hospital Muenster, 48149 Muenster, Germany."}], "LastName": "Hrincius", "ForeName": "Eike R", "Initials": "ER"}, {"Identifier": ["0000-0003-4490-3052"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Virology Muenster, Center for Molecular Biology of Inflammation (ZMBE), University Hospital Muenster, 48149 Muenster, Germany."}], "LastName": "Ludwig", "ForeName": "Stephan", "Initials": "S"}], "GrantList": [{"GrantID": "57403037", "Agency": "German Academic Exchange Service", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceuticals (Basel)", "NlmUniqueID": "101238453", "ISSNLinking": "1424-8247"}, "CoiStatement": "W.S. is the owner of Hirsch Apotheke, Luedenscheid, Germany, who is the major sponsor of this study. A.H., G.H., S.L., and W.S. filed a patent on the use of <i>Hypericum perforatum</i> and hypericin against SARS-CoV-2."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Drosten C., G\u00fcnther S., Preiser W., Van Der Werf S., Brodt H.-R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967\u20131976. doi: 10.1056/NEJMoa030747.", "ArticleIdList": ["10.1056/NEJMoa030747", "12690091"]}, {"Citation": "Zaki A.M., Van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814\u20131820. doi: 10.1056/NEJMoa1211721.", "ArticleIdList": ["10.1056/NEJMoa1211721", "23075143"]}, {"Citation": "Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727\u2013733. doi: 10.1056/NEJMoa2001017.", "ArticleIdList": ["10.1056/NEJMoa2001017", "PMC7092803", "31978945"]}, {"Citation": "Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506. doi: 10.1016/S0140-6736(20)30183-5.", "ArticleIdList": ["10.1016/S0140-6736(20)30183-5", "PMC7159299", "31986264"]}, {"Citation": "Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (C.S.G) The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536\u2013544. doi: 10.1038/s41564-020-0695-z.", "ArticleIdList": ["10.1038/s41564-020-0695-z", "PMC7095448", "32123347"]}, {"Citation": "Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165878. doi: 10.1016/j.bbadis.2020.165878.", "ArticleIdList": ["10.1016/j.bbadis.2020.165878", "PMC7293463", "32544429"]}, {"Citation": "Neuman B.W., Kiss G., Kunding A.H., Bhella D., Baksh M.F., Connelly S., Droese B., Klaus J.P., Makino S., Sawicki S.G. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 2011;174:11\u201322. doi: 10.1016/j.jsb.2010.11.021.", "ArticleIdList": ["10.1016/j.jsb.2010.11.021", "PMC4486061", "21130884"]}, {"Citation": "Ruch T.R., Machamer C.E. The coronavirus E protein: Assembly and beyond. Viruses. 2012;4:363\u2013382. doi: 10.3390/v4030363.", "ArticleIdList": ["10.3390/v4030363", "PMC3347032", "22590676"]}, {"Citation": "Risco C., Ant\u00f3n I.M., Enjuanes L., Carrascosa J.L. The transmissible gastroenteritis coronavirus contains a spherical core shell consisting of M and N proteins. J. Virol. 1996;70:4773\u20134777. doi: 10.1128/jvi.70.7.4773-4777.1996.", "ArticleIdList": ["10.1128/jvi.70.7.4773-4777.1996", "PMC190415", "8676505"]}, {"Citation": "Hoffmann M., Kleine-Weber H., Schroeder S., Kr\u00fcger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u2013280.e8. doi: 10.1016/j.cell.2020.02.052.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Shang J., Wan Y., Luo C., Ye G., Geng Q., Auerbach A., Li F. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 2020;117:11727\u201311734. doi: 10.1073/pnas.2003138117.", "ArticleIdList": ["10.1073/pnas.2003138117", "PMC7260975", "32376634"]}, {"Citation": "Seth S., Batra J., Srinivasan S. COVID-19: Targeting proteases in viral invasion and host immune response. Front. Mol. Biosci. 2020;7:215. doi: 10.3389/fmolb.2020.00215.", "ArticleIdList": ["10.3389/fmolb.2020.00215", "PMC7581869", "33195400"]}, {"Citation": "Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409\u2013424. doi: 10.1038/s41579-021-00573-0.", "ArticleIdList": ["10.1038/s41579-021-00573-0", "PMC8167834", "34075212"]}, {"Citation": "Koelle K., Martin M.A., Antia R., Lopman B., Dean N.E. The changing epidemiology of SARS-CoV-2. Science. 2022;375:1116\u20131121. doi: 10.1126/science.abm4915.", "ArticleIdList": ["10.1126/science.abm4915", "PMC9009722", "35271324"]}, {"Citation": "Juki\u010d M., Kores K., Jane\u017ei\u010d D., Bren U. Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints. Front. Chem. 2021;9:757826. doi: 10.3389/fchem.2021.757826.", "ArticleIdList": ["10.3389/fchem.2021.757826", "PMC8748264", "35028304"]}, {"Citation": "Assis L.C., de Castro A.A., de Jesus J., Nepovimova E., Kuca K., Ramalho T.C., La Porta F.A. Computational evidence for nitro derivatives of quinoline and quinoline N-oxide as low-cost alternative for the treatment of SARS-CoV-2 infection. Sci. Rep. 2021;11:6397. doi: 10.1038/s41598-021-85280-9.", "ArticleIdList": ["10.1038/s41598-021-85280-9", "PMC7973710", "33737545"]}, {"Citation": "Llivisaca-Contreras S.A., Naranjo-Mor\u00e1n J., Pino-Acosta A., Pieters L., Vanden Berghe W., Manzano P., Vargas-P\u00e9rez J., Le\u00f3n-Tamariz F., Cevallos-Cevallos J.M. Plants and natural products with activity against various types of coronaviruses: A review with focus on SARS-CoV-2. Molecules. 2021;26:4099. doi: 10.3390/molecules26134099.", "ArticleIdList": ["10.3390/molecules26134099", "PMC8271932", "34279439"]}, {"Citation": "Brglez Mojzer E., Knez Hrn\u010di\u010d M., \u0160kerget M., Knez \u017d., Bren U. Polyphenols: Extraction methods, antioxidative action, bioavailability and anticarcinogenic effects. Molecules. 2016;21:901. doi: 10.3390/molecules21070901.", "ArticleIdList": ["10.3390/molecules21070901", "PMC6273793", "27409600"]}, {"Citation": "Ehrhardt C., Hrincius E.R., Korte V., Mazur I., Droebner K., Poetter A., Dreschers S., Schmolke M., Planz O., Ludwig S. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antivir. Res. 2007;76:38\u201347. doi: 10.1016/j.antiviral.2007.05.002.", "ArticleIdList": ["10.1016/j.antiviral.2007.05.002", "17572513"]}, {"Citation": "Derksen A., Hensel A., Hafezi W., Herrmann F., Schmidt T.J., Ehrhardt C., Ludwig S., K\u00fchn J. 3-O-galloylated procyanidins from Rumex acetosa L. inhibit the attachment of influenza A virus. PLoS ONE. 2014;9:e110089. doi: 10.1371/journal.pone.0110089.", "ArticleIdList": ["10.1371/journal.pone.0110089", "PMC4193892", "25303676"]}, {"Citation": "Klemow K.M., Bartlow A., Crawford J., Kocher N., Shah J., Ritsick M.  Medical Attributes of St. John\u2019s Wort (Hypericum perforatum) In: Benzie I.F.F., Wachtel-Galor S., editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. CRC Press/Taylor & Francis; Boca Raton, FL, USA: 2011.  [(accessed on 11 April 2022)].  Chapter 11. Available online:  https://www.ncbi.nlm.nih.gov/books/NBK92750/"}, {"Citation": "Weber N., Murray B., North J., Wood S. The antiviral agent hypericin has in vitro activity against HSV-1 through non-specific association with viral and cellular membranes. Antivir. Chem. Chemother. 1994;5:83\u201390. doi: 10.1177/095632029400500204.", "ArticleIdList": ["10.1177/095632029400500204"]}, {"Citation": "Axarlis S., Mentis A., Demetzos C., Mitaku S., Skaltsounis A., Marselos M., Malamas M. Antiviral in vitro activity of Hypericum perforatum L. extract on the human cytomegalovirus (HCMV) Phytother. Res. 1998;12:507\u2013511. doi: 10.1002/(SICI)1099-1573(199811)12:7<507::AID-PTR370>3.0.CO;2-H.", "ArticleIdList": ["10.1002/(SICI)1099-1573(199811)12:7<507::AID-PTR370>3.0.CO;2-H"]}, {"Citation": "Pang R., Tao J., Zhang S., Zhu J., Yue X., Zhao L., Ye P., Zhu Y. In vitro anti-hepatitis B virus effect of Hypericum perforatum L. J. Huazhong Univ. Sci. Technol. 2010;30:98\u2013102. doi: 10.1007/s11596-010-0118-0.", "ArticleIdList": ["10.1007/s11596-010-0118-0", "20155464"]}, {"Citation": "Pu X.-Y., Liang J.-P., Wang X.-H., Xu T., Hua L.-Y., Shang R.-F., Liu Y., Xing Y.-M. Anti-influenza A virus effect of Hypericum perforatum L. extract. Virol. Sin. 2009;24:19\u201327. doi: 10.1007/s12250-009-2983-x.", "ArticleIdList": ["10.1007/s12250-009-2983-x"]}, {"Citation": "Xiuying P., Jianping L., Ruofeng S., Liye Z., Xuehong W., Yan L. Therapeutic efficacy of Hypericum perforatum L. extract for mice infected with an influenza A virus. Can. J. Physiol. Pharmacol. 2012;90:123\u2013130. doi: 10.1139/y11-111.", "ArticleIdList": ["10.1139/y11-111", "22260349"]}, {"Citation": "Maury W., Price J.P., Brindley M.A., Oh C., Neighbors J.D., Wiemer D.F., Wills N., Carpenter S., Hauck C., Murphy P. Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum. Virol. J. 2009;6:101. doi: 10.1186/1743-422X-6-101.", "ArticleIdList": ["10.1186/1743-422X-6-101", "PMC2716326", "19594941"]}, {"Citation": "Pu X.-y., Liang J.-p., Shang R.-f., Wang X.-h., Wang Z.-X., Hua L.-Y., Yu L. Influence of Hypericum perforatum extract on piglet infected with porcine respiratory and reproductive syndrome virus. Agric. Sci. China. 2009;8:730\u2013739. doi: 10.1016/S1671-2927(08)60272-2.", "ArticleIdList": ["10.1016/S1671-2927(08)60272-2"]}, {"Citation": "Shang R., He C., Chen J., Pu X., Liu Y., Hua L., Wang L., Liang J. Hypericum perforatum extract therapy for chickens experimentally infected with infectious bursal disease virus and its influence on immunity. Can. J. Vet. Res. 2012;76:180\u2013185.", "ArticleIdList": ["PMC3384280", "23277696"]}, {"Citation": "Chen H., Muhammad I., Zhang Y., Ren Y., Zhang R., Huang X., Diao L., Liu H., Li X., Sun X. Antiviral activity against infectious bronchitis virus and bioactive components of Hypericum perforatum L. Front. Pharmacol. 2019;10:1272. doi: 10.3389/fphar.2019.01272.", "ArticleIdList": ["10.3389/fphar.2019.01272", "PMC6830131", "31736754"]}, {"Citation": "Zhang Y., Chen H., Zou M., Oerlemans R., Shao C., Ren Y., Zhang R., Huang X., Li G., Cong Y. Hypericin Inhibit Alpha-Coronavirus Replication by Targeting 3CL Protease. Viruses. 2021;13:1825. doi: 10.3390/v13091825.", "ArticleIdList": ["10.3390/v13091825", "PMC8473218", "34578406"]}, {"Citation": "St. John\u2019s Wort Dry Extract, Quantified (01/2017:1874)  [(accessed on 11 April 2022)].  European Pharmacopoeia 10th Edition-European Directorate for the Quality of Medicines & Healthcare (EDQM) Available online:  https://extranet.edqm.eu/4DLink1/pdfs/chromatos/1874.pdf."}, {"Citation": "Reaxys Database.  [(accessed on 11 April 2022)].  Available online:  https://www.reaxys.com/"}, {"Citation": "Harder T., Koch J., Vygen-Bonnet S., K\u00fclper-Schiek W., Pilic A., Reda S., Scholz S., Wichmann O. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: Interim results of a living systematic review, 1 January to 14 May 2021. Eurosurveillance. 2021;26:2100563. doi: 10.2807/1560-7917.ES.2021.26.28.2100563.", "ArticleIdList": ["10.2807/1560-7917.ES.2021.26.28.2100563", "PMC8284046", "34269175"]}, {"Citation": "Casadevall A., Henderson J.P., Joyner M.J., Pirofski L.-A. SARS-CoV-2 variants and convalescent plasma: Reality, fallacies, and opportunities. J. Clin. Investig. 2021;131:e148832. doi: 10.1172/JCI148832.", "ArticleIdList": ["10.1172/JCI148832", "PMC8011895", "33621214"]}, {"Citation": "Nathan R., Shawa I., De La Torre I., Pustizzi J.M., Haustrup N., Patel D.R., Huhn G. A narrative review of the clinical practicalities of Bamlanivimab and Etesevimab antibody therapies for SARS-CoV-2. Infect. Dis. Ther. 2021;10:1933\u20131947. doi: 10.1007/s40121-021-00515-6.", "ArticleIdList": ["10.1007/s40121-021-00515-6", "PMC8353431", "34374951"]}, {"Citation": "Kmietowicz Z. COVID-19: Monoclonal Antibodies Authorised in US as Alternative to Vaccines for Certain Groups. BMJ. 2021;375:n3064. doi: 10.1136/bmj.n3064.", "ArticleIdList": ["10.1136/bmj.n3064", "34893506"]}, {"Citation": "Stebbing J., Nievas G.S., Falcone M., Youhanna S., Richardson P., Ottaviani S., Shen J.X., Sommerauer C., Tiseo G., Ghiadoni L. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci. Adv. 2021;7:eabe4724. doi: 10.1126/sciadv.abe4724.", "ArticleIdList": ["10.1126/sciadv.abe4724", "PMC7775747", "33187978"]}, {"Citation": "Jordan S.C., Zakowski P., Tran H.P., Smith E.A., Gaultier C., Marks G., Zabner R., Lowenstein H., Oft J., Bluen B. Compassionate use of tocilizumab for treatment of SARS-CoV-2 pneumonia. Clin. Infect. Dis. 2020;71:3168\u20133173. doi: 10.1093/cid/ciaa812.", "ArticleIdList": ["10.1093/cid/ciaa812", "PMC7337689", "32575124"]}, {"Citation": "Fern\u00e1ndez-Cruz A., Ruiz-Antor\u00e1n B., Mu\u00f1oz-G\u00f3mez A., Sancho-L\u00f3pez A., Mills-S\u00e1nchez P., Centeno-Soto G.A., Blanco-Alonso S., Javaloyes-Garachana L., Gal\u00e1n-G\u00f3mez A., Valencia-Alijo \u00c1. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob. Agents Chemother. 2020;64:e01168-20. doi: 10.1128/AAC.01168-20.", "ArticleIdList": ["10.1128/AAC.01168-20", "PMC7449182", "32571831"]}, {"Citation": "Kyriazopoulou E., Poulakou G., Milionis H., Metallidis S., Adamis G., Tsiakos K., Fragkou A., Rapti A., Damoulari C., Fantoni M. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial. Nat. Med. 2021;27:1752\u20131760. doi: 10.1038/s41591-021-01499-z.", "ArticleIdList": ["10.1038/s41591-021-01499-z", "PMC8516650", "34480127"]}, {"Citation": "Indari O., Jakhmola S., Manivannan E., Jha H.C. An update on antiviral therapy against SARS-CoV-2: How far have we come? Front. Pharmacol. 2021;12:632677. doi: 10.3389/fphar.2021.632677.", "ArticleIdList": ["10.3389/fphar.2021.632677", "PMC7982669", "33762954"]}, {"Citation": "Kumar S., \u00c7al\u0131\u015fkan D.M., Janowski J., Faist A., Conrad B.C.G., Lange J., Ludwig S., Brunotte L. Beyond vaccines: Clinical status of prospective COVID-19 therapeutics. Front. Immunol. 2021;12:752227. doi: 10.3389/fimmu.2021.752227.", "ArticleIdList": ["10.3389/fimmu.2021.752227", "PMC8519339", "34659259"]}, {"Citation": "Fischer W.A., Eron J.J., Holman W., Cohen M.S., Fang L., Szewczyk L.J., Sheahan T.P., Baric R., Mollan K.R., Wolfe C.R., et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci. Transl. Med. 2022;14:eabl7430. doi: 10.1126/scitranslmed.abl7430.", "ArticleIdList": ["10.1126/scitranslmed.abl7430", "34941423"]}, {"Citation": "Ledford H. COVID antiviral pills: What scientists still want to know. Nature. 2021;599:358\u2013359. doi: 10.1038/d41586-021-03074-5.", "ArticleIdList": ["10.1038/d41586-021-03074-5", "34759341"]}, {"Citation": "Wanzala W., Zessin K., Kyule N., Baumann M., Mathia E., Hassanali A. Ethnoveterinary Medicine: A Critical Review of its Evolution, Perception, Understanding and the Way Forward. Livest. Res. Rural. Dev. 2005;17"}, {"Citation": "Wei F., Ma S.-C., Ma L.-Y., But P.P.-H., Lin R.-C., Khan I.A. Antiviral Flavonoids from the Seeds of Aesculus c hinensis. J. Nat. Prod. 2004;67:650\u2013653. doi: 10.1021/np030470h.", "ArticleIdList": ["10.1021/np030470h", "15104496"]}, {"Citation": "Li S., Chen C., Zhang H., Guo H., Wang H., Wang L., Zhang X., Hua S., Yu J., Xiao P. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antivir. Res. 2005;67:18\u201323. doi: 10.1016/j.antiviral.2005.02.007.", "ArticleIdList": ["10.1016/j.antiviral.2005.02.007", "PMC7114104", "15885816"]}, {"Citation": "Kotwal G.J., Kaczmarek J.N., Leivers S., Ghebremariam Y.T., Kulkarni A.P., Bauer G., De Beer C., Preiser W., Mohamed A.R. Anti-HIV, Anti-Poxvirus, and Anti-SARS Activity of a Nontoxic, Acidic Plant Extract from the Trifollium Species Secomet-V/anti-Vac Suggests That It Contains a Novel Broad-Spectrum Antiviral. Ann. N. Y. Acad. Sci. USA. 2005;1056:293\u2013302. doi: 10.1196/annals.1352.014.", "ArticleIdList": ["10.1196/annals.1352.014", "PMC7167892", "16387696"]}, {"Citation": "Mukhtar M., Arshad M., Ahmad M., Pomerantz R.J., Wigdahl B., Parveen Z. Antiviral potentials of medicinal plants. Virus Res. 2008;131:111\u2013120. doi: 10.1016/j.virusres.2007.09.008.", "ArticleIdList": ["10.1016/j.virusres.2007.09.008", "PMC7114233", "17981353"]}, {"Citation": "Benarba B., Pandiella A. Medicinal plants as sources of active molecules against COVID-19. Front. Pharmacol. 2020;11:1189. doi: 10.3389/fphar.2020.01189.", "ArticleIdList": ["10.3389/fphar.2020.01189", "PMC7427466", "32848790"]}, {"Citation": "Adhikari B., Marasini B.P., Rayamajhee B., Bhattarai B.R., Lamichhane G., Khadayat K., Adhikari A., Khanal S., Parajuli N. Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: A review. Phytother. Res. 2021;35:1298\u20131312. doi: 10.1002/ptr.6893.", "ArticleIdList": ["10.1002/ptr.6893", "PMC7675695", "33037698"]}, {"Citation": "Mensah M.L., Komlaga G., Forkuo A.D., Firempong C., Anning A.K., Dickson R.A. Herbal Medicine. IntechOpen; London, UK: 2019. Toxicity and Safety Implications of Herbal Medicines Used in Africa. Chapter 5.", "ArticleIdList": ["10.5772/intechopen.72437"]}, {"Citation": "Bajrai L.H., El-Kafrawy S.A., Alnahas R.S., Azhar E.I. In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea. bioRxiv. 2021 doi: 10.1101/2021.01.11.426295.", "ArticleIdList": ["10.1101/2021.01.11.426295"]}, {"Citation": "Lenard J., Rabson A., Vanderoef R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncytia formation. Proc. Natl. Acad. Sci. USA. 1993;90:158\u2013162. doi: 10.1073/pnas.90.1.158.", "ArticleIdList": ["10.1073/pnas.90.1.158", "PMC45619", "7678335"]}, {"Citation": "Tang J., Colacino J.M., Larsen S.H., Spitzer W. Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses. Antivir. Res. 1990;13:313\u2013325. doi: 10.1016/0166-3542(90)90015-Y.", "ArticleIdList": ["10.1016/0166-3542(90)90015-Y", "1699494"]}, {"Citation": "Nayak D.P., Hui E.K.-W., Barman S. Assembly and budding of influenza virus. Virus Res. 2004;106:147\u2013165. doi: 10.1016/j.virusres.2004.08.012.", "ArticleIdList": ["10.1016/j.virusres.2004.08.012", "PMC7172797", "15567494"]}, {"Citation": "Klein S., Cortese M., Winter S.L., Wachsmuth-Melm M., Neufeldt C.J., Cerikan B., Stanifer M.L., Boulant S., Bartenschlager R., Chlanda P. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nat. Commun. 2020;11:5885. doi: 10.1038/s41467-020-19619-7.", "ArticleIdList": ["10.1038/s41467-020-19619-7", "PMC7676268", "33208793"]}, {"Citation": "Mettenleiter T.C. Budding events in herpesvirus morphogenesis. Virus Res. 2004;106:167\u2013180. doi: 10.1016/j.virusres.2004.08.013.", "ArticleIdList": ["10.1016/j.virusres.2004.08.013", "15567495"]}, {"Citation": "Kocanova S., Hornakova T., Hritz J., Jancura D., Chorvat Jr D., Mateasik A., Ulicny J., Refregiers M., Maurizot J.C., Miskovsky P. Characterization of the Interaction of Hypericin with Protein Kinase C in U-87 MG Human Glioma Cells. Photochem. Photobiol. 2006;82:720\u2013728. doi: 10.1562/2005-09-26-RA-696.", "ArticleIdList": ["10.1562/2005-09-26-RA-696", "16396605"]}, {"Citation": "Singh S., Sarma S., Katiyar S.P., Das M., Bhardwaj R., Sundar D., Dubey V.K. Probing the molecular mechanism of hypericin-induced parasite death provides insight into the role of spermidine beyond redox metabolism in Leishmania donovani. Antimicrob. Agents Chemother. 2015;59:15\u201324. doi: 10.1128/AAC.04169-14.", "ArticleIdList": ["10.1128/AAC.04169-14", "PMC4291343", "25313212"]}, {"Citation": "Yal\u00e7\u0131n S., Yal\u00e7\u0131nkaya S., Ercan F. Determination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatment. Curr. Pharmacol. Rep. 2021;7:42\u201348. doi: 10.1007/s40495-021-00254-9.", "ArticleIdList": ["10.1007/s40495-021-00254-9", "PMC7921287", "33680715"]}, {"Citation": "Matos A.D.R., Caetano B.C., Martins J.S.C.D.C., Oliveira M.G.P.d., Sousa T.d.C., Horta M.A.P., Siqueira M.M., Fernandez J.H. Identification of Hypericin as a candidate repurposed therapeutic agent for COVID-19 and its potential anti-SARS-CoV-2 activity. Front. Microbiol. 2022;13:828984. doi: 10.3389/fmicb.2022.828984.", "ArticleIdList": ["10.3389/fmicb.2022.828984", "PMC8866965", "35222340"]}, {"Citation": "Mahmoudi S., Balmeh N., Mohammadi N., Sadeghian-Rizi T. The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds. Avicenna J. Med. Biotechnol. 2021;13:107\u2013115. doi: 10.18502/ajmb.v13i3.6370.", "ArticleIdList": ["10.18502/ajmb.v13i3.6370", "PMC8377408", "34484639"]}, {"Citation": "Bahun M., Juki\u0107 M., Oblak D., Kranjc L., Bajc G., Butala M., Bozovi\u010dar K., Bratkovi\u010d T., Podlipnik \u010c., Ulrih N.P. Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols. Food Chem. 2022;373:131594. doi: 10.1016/j.foodchem.2021.131594.", "ArticleIdList": ["10.1016/j.foodchem.2021.131594", "PMC8592230", "34838409"]}, {"Citation": "Zirak N., Shafiee M., Soltani G., Mirzaei M., Sahebkar A. Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. J. Cell. Physiol. 2019;234:8496\u20138508. doi: 10.1002/jcp.27781.", "ArticleIdList": ["10.1002/jcp.27781", "30461013"]}, {"Citation": "Peterson B., Nguyen H.  StatPearls. St. John\u2019s Wort; Treasure Island, FL, USA: 2022.  [(accessed on 23 March 2022)].  Available online:  https://www.ncbi.nlm.nih.gov/books/NBK557465/"}, {"Citation": "Ng Q.X., Venkatanarayanan N., Ho C.Y.X. Clinical use of Hypericum perforatum (St John\u2019s wort) in depression: A meta-analysis. J. Affect. Disord. 2017;210:211\u2013221. doi: 10.1016/j.jad.2016.12.048.", "ArticleIdList": ["10.1016/j.jad.2016.12.048", "28064110"]}, {"Citation": "Eatemadnia A., Ansari S., Abedi P., Najar S. The effect of Hypericum perforatum on postmenopausal symptoms and depression: A randomized controlled trial. Complementary Ther. Med. 2019;45:109\u2013113. doi: 10.1016/j.ctim.2019.05.028.", "ArticleIdList": ["10.1016/j.ctim.2019.05.028", "31331546"]}, {"Citation": "Schulz H.-U., Sch\u00fcrer M., B\u00e4ssler D., Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung. 2005;55:15\u201322. doi: 10.1055/s-0031-1296820.", "ArticleIdList": ["10.1055/s-0031-1296820", "15727160"]}, {"Citation": "Kerb R., Brockm\u00f6ller J., Staffeldt B., Ploch M., Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob. Agents Chemother. 1996;40:2087\u20132093. doi: 10.1128/AAC.40.9.2087.", "ArticleIdList": ["10.1128/AAC.40.9.2087", "PMC163478", "8878586"]}, {"Citation": "Lavie G., Mazur Y., Lavie D., Prince A., Pascual D., Liebes L., Levin B., Meruelo D. Hypericin as an inactivator of infectious viruses in blood components. Transfusion. 1995;35:392\u2013400. doi: 10.1046/j.1537-2995.1995.35595259149.x.", "ArticleIdList": ["10.1046/j.1537-2995.1995.35595259149.x", "7740610"]}, {"Citation": "Miskovsky P., Hritz J., Sanchez-Cortes S., Fabriciova G., Ulicny J., Chinsky L. Interaction of Hypericin with Serum Albumins: Surface-enhanced Raman Spectroscopy, Resonance Raman Spectroscopy and Molecular Modeling Study. Photochem. Photobiol. 2001;74:172\u2013183. doi: 10.1562/0031-8655(2001)074<0172:IOHWSA>2.0.CO;2.", "ArticleIdList": ["10.1562/0031-8655(2001)074<0172:IOHWSA>2.0.CO;2", "11547551"]}, {"Citation": "Masiello P., Novelli M., Beffy P., Menegazzi M. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients? Phytother. Res. 2020;34:1471\u20131473. doi: 10.1002/ptr.6764.", "ArticleIdList": ["10.1002/ptr.6764", "PMC7300500", "32501634"]}, {"Citation": "Havranek K.E., Jimenez A.R., Acciani M.D., Lay Mendoza M.F., Reyes Ballista J.M., Diaz D.A., Brindley M.A. SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. Viruses. 2020;12:1465. doi: 10.3390/v12121465.", "ArticleIdList": ["10.3390/v12121465", "PMC7767099", "33353101"]}, {"Citation": "Zettl F., Meister T.L., Vollmer T., Fischer B., Steinmann J., Krawczyk A., V\u2019kovski P., Todt D., Steinmann E., Pfaender S. Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes. Vaccines. 2020;8:386. doi: 10.3390/vaccines8030386.", "ArticleIdList": ["10.3390/vaccines8030386", "PMC7563800", "32679691"]}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55\u201363. doi: 10.1016/0022-1759(83)90303-4.", "ArticleIdList": ["10.1016/0022-1759(83)90303-4", "6606682"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "3", "Day": "23"}, {"Year": "2022", "Month": "4", "Day": "15"}, {"Year": "2022", "Month": "4", "Day": "17"}, {"Year": "2022", "Month": "5", "Day": "28", "Hour": "1", "Minute": "38"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "29", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "4", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["35631357", "PMC9146521", "10.3390/ph15050530", "ph15050530"]}}], "PubmedBookArticle": []}